AR123629A1 - Cepas novedosas de pasteurella multocida y vacunas que tienen supresiones en hyac y nanp - Google Patents

Cepas novedosas de pasteurella multocida y vacunas que tienen supresiones en hyac y nanp

Info

Publication number
AR123629A1
AR123629A1 ARP210102690A ARP210102690A AR123629A1 AR 123629 A1 AR123629 A1 AR 123629A1 AR P210102690 A ARP210102690 A AR P210102690A AR P210102690 A ARP210102690 A AR P210102690A AR 123629 A1 AR123629 A1 AR 123629A1
Authority
AR
Argentina
Prior art keywords
multocida
hyac
nanp
gene
pasteurella multocida
Prior art date
Application number
ARP210102690A
Other languages
English (en)
Inventor
Robert E Briggs
Fred M Tatum
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of AR123629A1 publication Critical patent/AR123629A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01022—UDP-glucose 6-dehydrogenase (1.1.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03029—N-Acylneuraminate-9-phosphatase (3.1.3.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona cepas atenuadas novedosas de Pasteurella multocida que se pueden utilizar, en forma viva o muerta, para formular vacunas que son altamente protectoras contra la infección por P. multocida en bovinos, otros mamíferos y en las aves. La presente invención identifica también la combinación de mutaciones de genes nanP y hyaC como clave para la provisión de tales vacunas. Cuando se formula apropiadamente, el material antigénico de numerosos otros patógenos bovinos se puede combinar con las cepas vivas atenuadas de Pasteurella multocida para fabricar vacunas combinadas eficaces. Reivindicación 1: Una bacteria Pasteurella multocida (P. multocida) viva atenuada que comprende un gen hyaC con al menos una mutación atenuante, y un gen nanP con al menos una mutación atenuante. Reivindicación 15: Una bacteria Pasteurella multocida (P. multocida) de serogrupo A en donde los genes de virulencia hyaC, nanP de tipo salvaje, y, opcionalmente, uno o más de Fis, o de la leucotoxina A son modificados de tal modo que la bacteria es atenuada. Reivindicación 16: Una bacteria Pasteurella multocida (P. multocida) aislada y muerta o bacterina defectiva para la biosíntesis de ácido hialurónico que es el resultado de una mutación en el gen hyaC, y defectiva para la sialilación superficial que es resultado de una mutación en el gen nanP.
ARP210102690A 2020-09-30 2021-09-28 Cepas novedosas de pasteurella multocida y vacunas que tienen supresiones en hyac y nanp AR123629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063085495P 2020-09-30 2020-09-30

Publications (1)

Publication Number Publication Date
AR123629A1 true AR123629A1 (es) 2022-12-28

Family

ID=80821057

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102690A AR123629A1 (es) 2020-09-30 2021-09-28 Cepas novedosas de pasteurella multocida y vacunas que tienen supresiones en hyac y nanp

Country Status (4)

Country Link
US (1) US12071636B2 (es)
AR (1) AR123629A1 (es)
TW (1) TW202219269A (es)
WO (1) WO2022072232A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010207A (es) 1999-04-09 2003-07-21 Pharmacia & Upjohn Inc Composiciones de vacuna antibacteriana.
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
WO2008118902A1 (en) 2007-03-26 2008-10-02 Wyeth Vaccination against multiple serotypes of pasteurella multocida
ES2824402T3 (es) 2013-11-01 2021-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas
US10039818B2 (en) 2016-05-05 2018-08-07 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated pasteurella multocida strains

Also Published As

Publication number Publication date
US12071636B2 (en) 2024-08-27
WO2022072232A1 (en) 2022-04-07
TW202219269A (zh) 2022-05-16
US20220098558A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
BR112018076633A2 (pt) mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk
MX2010005014A (es) Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
CL2008003202A1 (es) Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
Wang et al. Live-attenuated Yersinia pestis vaccines
BRPI0821286A8 (pt) Métodos e composições para imunizar porcos contra circovirus suino
CO6460761A2 (es) Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento
AR123629A1 (es) Cepas novedosas de pasteurella multocida y vacunas que tienen supresiones en hyac y nanp
HK1145627A1 (en) Attenuated mycoplasma gallisepticum strains
CN111182920B (zh) 针对抗原的保护性免疫的诱导
RU2011133824A (ru) Фармацевтическая композиция для защиты животного от растройства, возникающего в результате инфекции бактерий, которая относится к группе нокардиоформных актиномицетов
ME01002B (me) Vakcina i imunogenične kompozicije za virus plavog jezika, postupci za njihovu upotrebu i postupci za njihovu izradu
Srilunchang et al. Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2
AR123664A1 (es) Nuevas cepas de pasteurella multocida y vacunas que tienen deleciones de hyac y nanp
CA2713097A1 (en) Vaccines
BR112023005001A2 (pt) Isolado atenuado do vírus da estirpe dmv1639 de bronquite infecciosa
Jiang et al. Preclinical evaluation of OMVs as potential vaccine candidates against Salmonella enterica serovar Enteritidis infection
EP3186363B1 (en) Vaccine for livestock production systems
Grózner et al. Kacsák és ludak Mycoplasma-fertőzései.
EP4233912A3 (en) Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
RU2009143526A (ru) Комбинации из делеций генов для живых ослабленных вакцинных штаммов shigella
WO2016013873A1 (ko) Ｒｖ３１１２, ＭＴＢＫ ２０６２０ 또는 ＭＴＢＫ ２４８２０ 단백질을 포함하는 결핵 예방용 백신 조성물
Guo et al. Construction and virulence of filamentous hemagglutinin protein B1 mutant of Pasteurella multocida in chickens
WO2020145426A1 (ko) 방사선에 의한 약독화 생균 백신의 제조 방법 및 이로부터 제조된 약독화 생균 백신 조성물
Ehsan Mycoplasma gallisepticum and Mycoplasma synoviae Live Vaccine Development and Evaluation
MX2023007814A (es) Composiciones inmunogenicas y vacunales contra la disenteria porcina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure